Macular Degeneration (AMD)



Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator


Condition:   Age-related Macular Degeneration
Intervention:  
Sponsor:   University of Alabama at Birmingham
Not yet recruiting - verified May 2017


Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal


Condition:   Age-Related Macular Degeneration
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Recruiting - verified September 2016


Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration


Condition:   Macular Degeneration
Intervention:   Device: Ocusweep system
Sponsor:   Turku University Hospital
Enrolling by invitation - verified April 2017


Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration


Condition:   Neovascular Age-related Macular Degeneration
Intervention:   Biological: TK001
Sponsor:   Jiangsu T-Mab Biopharma Co.,Ltd
Recruiting - verified September 2016


Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye


Condition:   Macular Degeneration
Interventions:   Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);   Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Sponsor:   Bayer
Recruiting - verified May 2017


A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:   Drug: DE-122
Sponsor:   Santen Inc.
Active, not recruiting - verified May 2017


Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)


Condition:   Macular Degeneration
Intervention:   Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors:   Bayer;   Regeneron Pharmaceuticals
Recruiting - verified May 2017


Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan


Condition:   Wet Macular Degeneration
Intervention:   Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors:   Bayer;   Regeneron Pharmaceuticals
Completed - verified August 2016


A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Interventions:   Drug: DE-120;   Drug: Aflibercept
Sponsor:   Santen Inc.
Completed - verified May 2017


Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration


Condition:   Wet Macular Degeneration
Intervention:   Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors:   Bayer;   Regeneron Pharmaceuticals
Active, not recruiting - verified April 2017


Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration


Condition:   Macular Degeneration
Interventions:   Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506);   Procedure: Sham IVT;   Drug: Ranibizumab;   Drug: Placebo
Sponsor:   Bayer
Terminated - verified July 2016


A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:   Drug: DE-120
Sponsor:   Santen Inc.
Completed - verified May 2017


A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics


Condition:   Wet Age-related Macular Degeneration
Intervention:  
Sponsor:   Novartis Pharmaceuticals
Terminated - verified February 2017


Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections


Condition:   Age Related Macular Degeneration
Intervention:   Drug: Aflibercept
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified October 2016


Proton Radiation Therapy for Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:   Radiation: Proton radiation
Sponsor:   University of Florida
Active, not recruiting - verified March 2017


Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)


Condition:   Age-related Macular Degeneration
Interventions:   Drug: Omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3;   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
Sponsors:   Brigham and Women's Hospital;   National Eye Institute (NEI)
Active, not recruiting - verified January 2017


Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration


Conditions:   Age-Related Macular Degeneration;   Macular Degeneration
Interventions:   Drug: Intravitreal Aflibercept Injection More;   Drug: Intravitreal Aflibercept Injection Less
Sponsors:   MidAtlantic Retina;   Regeneron Pharmaceuticals
Completed - verified February 2017


Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration


Condition:   Macular Degeneration
Intervention:   Dietary Supplement: Omega-3 fatty acid
Sponsors:   Wills Eye;   Physician Recommended Nutriceuticals
Completed - verified December 2016


Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration


Condition:   Age Related Macular Degeneration
Interventions:   Device: Telescope prosthesis;   Device: WA-NG Telescope Prothesis
Sponsor:   VisionCare, Inc.
Withdrawn - verified October 2016


Study of Dark Adaptation in Age-Related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:  
Sponsor:   National Eye Institute (NEI)
Recruiting - verified March 15, 2017


Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)


Condition:   Age Related Macular Degeneration
Intervention:   Drug: Subretinally injected RetinoStat
Sponsor:   Oxford BioMedica
Completed - verified April 2017


High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration


Condition:   Macular Degeneration
Intervention:  
Sponsor:   National Eye Institute (NEI)
Completed - verified August 19, 2014


Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy


Condition:   Age-related Macular Degeneration
Intervention:  
Sponsor:   University Hospital, Bonn
Active, not recruiting - verified May 2017


Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration


Condition:   Macular Degeneration
Interventions:   Drug: TAC-PF;   Drug: Triamcinolone Acetonide
Sponsor:   National Eye Institute (NEI)
Completed - verified December 20, 2006


Genetic Factors in Age-Related Macular Degeneration


Condition:   Macular Degeneration
Intervention:  
Sponsor:   National Eye Institute (NEI)
Terminated - verified October 21, 2015

Refine Your Search Advanced Search